PFE

PFIZER INC

Healthcare • USA

Apr 05 • 04:00PM ET
22.83
+0.23 (+1.02%)
Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It ... read more

Full Time Employees 88,000
Phone 212 733 2323
Website https://www.pfizer.com
CEO Dr. Albert Bourla D.V.M., Ph.D.
IPO Date 1972-06-01
Sector Healthcare
Industry Drug Manufacturers - General
Address 235 East 42nd Street, New York, NY 10017
Balance Sheet
Total Cash $1,430,000,000
Total Debt $62,109,000,000
Current Ratio 1.26
Quick Ratio 0.80
Profitability
Gross Margin 72.28%
Net Margin 12.62%
ROE 8.73%
ROA 3.79%
ROIC 5.18%
Balance Sheet
Total Cash $1,430,000,000
Total Debt $62,109,000,000
Current Ratio 1.26
Quick Ratio 0.80
Profitability
Gross Margin 72.28%
Net Margin 12.62%
ROE 8.73%
ROA 3.79%
ROIC 5.18%
Name PFIZER INC Sector Healthcare Currency USD Relative Volume 1.72 Market Cap 130178
Current Ratio 1.17 Dividend / Share 1.68 EPS 1.41 Revenue 63627000000 P/S 2.0
P/E 16.2 Beta 0.24 Income 8031000000 Volume 79475986 Average Volume 46282413
Distance to 200DMA -16.35% 200 DMA 27.46 50 DMA 25.89 ROA 3.7 ROE 8.9
Distance to 50DMA -11.28% Return 1Y -10.37% Return YTD -11.99% Forward PE Qtly Growth YOY
Debt/Eq 1.42 P/B 1.5 Dividend Yield 6.3% Net Margin 12.62% Payout Ratio 118.3
Performance
52 Week Range 118.3%
Distance to 200DMA 1.84%
Day Change Percent $0.42
Performance Week $0.42
Performance Month $0.42
Performance Quarter 2024-07-26
Performance YTD $0.42
Performance Year $0.42

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $1,092,000,000
Total Debt $67,701,000,000
Current Ratio 1.00%
Quick Ratio 0.36%
Profitability
Gross Margin 72.28%
Net Margin 12.62%
ROE 8.73%
ROA 3.79%
ROIC 5.18%
Valuation
Price to Earnings 16.44
Price to Book 1.43
Price to Sales 2.07
Price to Free Cash Flow 11.55
Dividends
Payout Ratio 121.66%
Dividend Yield 7.40%
Dividend Amount $0.42
Last Dividend Pay Date 2024-07-26
Last Dividend Paid $0.42
Performance
52 Week Range 118.3%
Distance to 200DMA 1.84%
Day Change Percent $0.42
Performance Week $0.42
Performance Month $0.42
Performance Quarter 2024-07-26
Performance YTD $0.42
Performance Year $0.42
Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It ... read more

Full Time Employees 88,000
Phone 212 733 2323
Website https://www.pfizer.com
CEO Dr. Albert Bourla D.V.M., Ph.D.
IPO Date 1972-06-01
Sector Healthcare
Address 235 East 42nd Street, New York, NY 10017
Histogram - Daily

Balance Sheet
Total Cash $1,092,000,000
Total Debt $67,701,000,000
Current Ratio 1.00%
Quick Ratio 0.36%
Profitability
Gross Margin 0.6760%
Net Margin 0.0710%
ROE 0.05%
ROA 0.02%
Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It ... read more

Full Time Employees 88,000
Phone 212 733 2323
Website https://www.pfizer.com
CEO Dr. Albert Bourla D.V.M., Ph.D.
IPO Date 1972-06-01
Sector Healthcare
Address 235 East 42nd Street, New York, NY 10017
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

US House panel seeks information from Pfizer over alleged COVID vaccine delay
US House panel seeks information from Pfizer over alleged COVID vaccine delay

U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 va

2025-05-15 17:18:47 - reuters.com
New allegations about timing of Pfizer Covid vaccine passed to House panel
New allegations about timing of Pfizer Covid vaccine passed to House panel

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.

2025-05-15 11:20:00 - wsj.com
5 Low Price-to-Book Value Stocks to Buy in May
5 Low Price-to-Book Value Stocks to Buy in May

The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.

2025-05-15 09:41:13 - zacks.com
Dividend Harvesting Portfolio Week 219: $21,900 Allocated, $2,206.52 In Projected Dividends
Dividend Harvesting Portfolio Week 219: $21,900 Allocated, $2,206.52 In Projecte

I'm bullish on the second half of 2025, expecting further market gains if CPI trends lower and trade talks progress positively. Despite a small portfolio decline this week, my Dividend Harvesting Port

2025-05-15 09:00:00 - seekingalpha.com
3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Forever
3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold For

With China and the United States finally talking to one another regarding tariffs, there's a glimmer of hope on the macroeconomic horizon. Investors might want to continue thinking and acting defensiv

2025-05-14 18:05:00 - fool.com
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer

Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors t

2025-05-14 16:36:16 - seekingalpha.com
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pf

Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albe

2025-05-14 03:41:13 - reuters.com
PFE vs. LLY: Which Stock Is the Better Value Option?
PFE vs. LLY: Which Stock Is the Better Value Option?

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those

2025-05-13 12:45:41 - zacks.com
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.

2025-05-13 11:40:33 - zacks.com
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.

2025-05-13 11:18:00 - barrons.com
Should Value Investors Buy Pfizer (PFE) Stock?
Should Value Investors Buy Pfizer (PFE) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

2025-05-13 10:45:47 - zacks.com
US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop
US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop

A surprising thaw in US-China trade relations sparked significant optimism on Wall Street Monday. This positive development, coupled with lower recession odds, sets up a bullish long-term outlook for

2025-05-13 10:01:09 - zacks.com
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared

President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.

2025-05-13 08:40:53 - zacks.com
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy

Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,

2025-05-12 18:25:11 - seekingalpha.com